Resmed (RMD) stock
Last close $236.88 on 2026-11-19 (-2.36%) · Sector: Healthcare
ResMed (NYSE: RMD) makes medical devices and software that help people with breathing and sleep conditions, such as sleep apnea, get treated at home instead of in a hospital. It earns most of its money by selling masks, machines, and related supplies and services, often on a recurring basis as patients keep using them.
ResMed is financially healthy, with strong profit margins, very little debt, and revenue that grew 8.7% over the last year. The stock has lagged the S&P 500 over the past year, returning -2.9% versus the index's 9.7%, and it sits 14.7% below its 52-week high. Insiders sold about $3.8 million of stock over the last 90 days and made no purchases, and the stock has more often fallen than risen the day after earnings reports.
Key numbers
- Market cap: $34.0B
- Revenue (last 12 months): $5.72B
- Revenue growth: +8.7%
- Gross margin: 61.1%
- Operating margin: 33.0%
- P/E: 21.6
- P/S: 5.9
- Debt to equity: 0.04
- Current ratio: 2.66
Quality score
Overall 55/100 · growth 37 · profitability 60 · financial health 80 · value 43
Performance and risk
1-year return -2.9% vs S&P 500 +9.7% · volatility 30.9% (S&P 500 13.8%) · largest drop -33.8% · beta 0.51
Stock move the day after earnings
- 2026-01-29: +0.3%
- 2026-04-30: -4.1%
- 2026-07-07: -6.3%
- 2026-08-06: -5.1%
- 2026-10-29: -9.1%
Insider trades (12 months)
Bought $0.0M · sold $20.1M
RMD stock research · RMD options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.